Wyss Institute

What Wyss Institute does

The Wyss Institute for Biologically Inspired Engineering is a Harvard University research institute founded in 2009 with a $125 million donation from Hansjörg Wyss, headquartered at 201 Brookline Avenue in Boston. It develops biologically inspired materials and devices — including Human Organs-on-Chips (microfluidic devices lined with living human cells that mimic lung, intestine, kidney, and bone marrow function), the dSHERLOCK CRISPR-based diagnostic platform, Implantable Living Materials for on-demand drug delivery, RNA immunotherapeutics, and the AI DataHub for ML-driven drug discovery and biomarker development. Its work spans drug development, disease modeling, personalized medicine, infectious disease diagnostics, and environmental sustainability challenges.

The institute operates a hybrid translational model rather than a conventional product business. It is funded primarily through federal research grants (ARPA-H, DARPA, NIH, NASA — including $27M from ARPA-H in 2024 for RNA therapeutics and $25M in 2025 from the ARPA-H PRINT program for 3D bioprinting) and philanthropy, supplemented by direct pharmaceutical collaborations with AstraZeneca and Johnson & Johnson. It commercializes IP through startup spin-outs — Emulate (Organ Chips, launched 2014, $200M+ raised), Prapela (infant health vibrating mattress, 2018), Manifold Bio (protein barcoding, 2020, $40M Series A), Unravel Biosciences (AI drug discovery for rare diseases, 2021), Dyno Therapeutics (AAV engineering), and Cerulean Scientific (medical device coatings, ~$20M in NIH/CDMRP grants) — typically retaining minority stakes. Its 2022 contribution to the FDA Modernization Act 2.0 and integration with 12+ academic and hospital partners (including MIT, Brigham and Women's, MGH, Boston Children's, Charité Berlin, and University of Zurich) position it as a structurally embedded translation engine rather than a standalone commercial enterprise.

Name

Wyss Institute

Legal name

Hansjörg Wyss Institute for Biologically Inspired Engineering at Harvard University

Website

https://wyss.harvard.edu

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

251–500 employees

Short description

The Wyss Institute for Biologically Inspired Engineering at Harvard University develops bioinspired materials, organ-on-chip technology, diagnostics, and AI platforms to address healthcare and sustainability challenges, commercializing discoveries through licensing, spin-out startups, and pharmaceutical partnerships.

Ownership category

akta.pro rank

Product category

Biomedical Research and Technology Licensing

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA), Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK), Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• Biologically inspired engineering
• Organs-on-chips technology
• Biomedical research institute
• Drug discovery platforms
• Biotechnology technology licensing

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Others

Revenue model

1. Technology Licensing: Licensing of patented technologies and IP to established companies for commercialization. Examples include licensing to Emulate, Prapela, Manifold Bio, and others.
2. Startup Formation: Spin-out companies formed from Wyss research to commercialize specific technologies, such as Emulate (Organ Chips), Prapela (infant health devices), Manifold Bio (protein therapeutics), and others.
3. Government Research Grants: Major funding from federal agencies including ARPA-H ($27M for RNA therapeutics), DARPA, NIH for various research programs and validation projects.
4. Collaborative Research Agreements: Direct partnerships with pharmaceutical companies like AstraZeneca and Johnson & Johnson for drug development using Organ Chips and other technologies.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

The Wyss Institute develops biologically inspired materials, devices, and platform technologies for healthcare and sustainability. Core offerings include Human Organs-on-Chips (microfluidic devices mimicking human organ function), the AI DataHub (AI-integrated biological data platform for drug discovery), the Diagnostics for Human and Planetary Health Platform, CRISPR-based diagnostics (dSHERLOCK), protein barcoding platforms, and RNA immunotherapeutics. Technologies are commercialized through licensing agreements, startup formation, and collaborative research with pharmaceutical companies and government agencies.

Product overview

The Wyss Institute develops a portfolio of biologically inspired technologies primarily focused on healthcare applications. The core offerings include Human Organs-on-Chips (microfluidic devices for drug testing), the AI DataHub (for AI-accelerated drug discovery), and the Diagnostics for Human and Planetary Health Platform. These are complemented by spun-out startups including Emulate, Inc. (commercializing Organ Chips), Manifold Bio (protein therapeutic development), and Prapela (infant health devices). The institute also operates Translational AI Catalyst for cross-functional AI initiatives. The portfolio spans from early-stage research technologies like the Multiplexed Protein Binding and Barcoding Platform to validated products like the Active Mattress for Infant Health.

Differentiator

Problem solved

Functional benefit

Brands

• Human Organs-on-Chips: Microfluidic devices lined with living human cells for drug development, disease modeling, and personalized medicine
• Lumineers
• Translational AI Catalyst
• AI DataHub
• Diagnostics for Human and Planetary Health
• Wyss DxA
• Brain Targeting Program
• Reimagine the World

Products and services

• Human Organs-on-Chips Microfluidic devices lined with living human cells that recreate organ-level functions (lung, intestine, kidney, bone marrow, liver, brain) for drug testing, disease modeling, and personalized medicine. Licensed to Emulate, Inc. and installed in over 150 labs including 17 of the top 25 global biopharmaceutical companies.
• AI DataHub AI platform that integrates biological data and tissue models including Organ Chips, organoid cultures, and animal model datasets combined with machine learning and multi-omics capabilities to accelerate drug discovery and biomarker development.
• Diagnostics for Human and Planetary Health Platform

Quantifiable outcome

• Reduces drug development timelines from 10+ years to months
• +4 more outcomes

Named customers5 records

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature8 records

Partnerships

19 partnerships are on record, tiered core and flagship.

• Harvard Medical SchoolcoreStrategic or Co-development PartnerWyss Institute is part of Harvard University's ecosystem, working closely with Harvard Medical School faculty and researchers on biological engineering innovations.
• MITcoreStrategic or Co-development PartnerCollaboration with MIT on various research projects including Brain Targeting Program, AI-enabled drug discovery, and machine learning for antibiotic discovery.
• Brigham and Women's HospitalcoreStrategic or Co-development PartnerClinical partner providing access to patient samples, clinical expertise, and collaboration on diagnostic and therapeutic development through the Brigham-Wyss DxA.
• Massachusetts General HospitalcoreStrategic or Co-development PartnerClinical collaboration on various research projects including infectious disease therapeutics and diagnostics development.
• NASAcoreStrategic or Co-development PartnerNASA AVATAR program using Organ Chips on Artemis II mission to study effects of deep space radiation on human health for astronaut safety.
• AstraZenecacoreStrategic or Co-development PartnerStrategic collaboration using Organ Chips to better predict human response in drug development process.
• Johnson & JohnsoncoreStrategic or Co-development PartnerStrategic collaboration using Organ Chips platform to better predict human response in drug development process.
• Broad InstitutecoreStrategic or Co-development PartnerCollaboration on machine learning-driven antibiotic discovery research for drug-resistant gonorrhea.
• Tufts UniversitycoreStrategic or Co-development PartnerAcademic partner collaborating on neurobot research and biological machines development.
• Boston UniversitycoreStrategic or Co-development PartnerCollaboration on ESCAPE technique for 3D biofabrication of human tissue structures using gallium.
• Charité BerlincoreStrategic or Co-development PartnerInternational academic partner in the Wyss consortium for biological engineering research.
• University of ZurichcoreStrategic or Co-development PartnerInternational academic partner collaborating on various research initiatives including Wyss Zurich.
• Emulate, Inc.flagshipOEM/ Whitelabel/ Licensing PartnerSpin-off company commercializing Human Organs-on-Chips technology. Launched in 2014, installed in 150+ labs including top pharma companies.
• PrapelacoreOEM/ Whitelabel/ Licensing PartnerStartup commercializing vibrating mattress technology for infant health conditions including apnea and neonatal opioid withdrawal syndrome.
• Manifold BiocoreOEM/ Whitelabel/ Licensing PartnerStartup commercializing multiplexed protein binding and barcoding platform for drug development, raised $5.4M seed and $40M Series A.
• Cerulean ScientificcoreOEM/ Whitelabel/ Licensing PartnerMedical device startup developing implants and catheters using tethered liquid perfluorocarbon coating technology licensed from Wyss Institute.
• Cerulean ScientificcoreOEM/ Whitelabel/ Licensing PartnerCerulean Scientific has raised nearly $20 million in grants from NIH and Congressionally Directed Medical Research Programs to develop coated medical devices.
• Unravel BiosciencescoreOEM/ Whitelabel/ Licensing PartnerSpun out from Wyss Institute in 2021 to commercialize nemoCAD/BioNAV AI platform for drug discovery; received FDA Orphan Drug Designation for Rett syndrome treatment.
• Dyno TherapeuticscoreOEM/ Whitelabel/ Licensing PartnerStartup commercializing AI-powered AAV capsid engineering technology for gene therapy delivery.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• TissUse GmbH: Berlin-based organ-on-chip and multi-organ-chip developer with HUMIMIC platform. Comparable to Wyss/Emulate on Organ Chip product category and pharma customer base, with strength in European markets and toxicology applications.

Broad incumbents

• Gladstone Institutes: San Francisco-based nonprofit biomedical research institute affiliated with UCSF. Comparable academic-research-translation model to Wyss, focused on cardiovascular, neurological, and infectious disease research with spinout activity.
• Koch Institute for Integrative Cancer Research (MIT): MIT cancer research institute with similar model of translating bioengineering breakthroughs into commercial applications. Comparable in academic-industry translation framework and Boston/Cambridge location, though focused specifically on oncology.
• Howard Hughes Medical Institute (HHMI): Largest US biomedical research organization funding Investigator-led science with commercialization pathways. Comparable to Wyss as a large, well-funded biomedical research engine that supports faculty-driven discovery and translation.

Direct peers

• Emulate, Inc. Direct spinout commercializing Wyss's Human Organs-on-Chips technology. Installed in 150+ labs including 17 of top 25 biopharma and used by the FDA — the most direct commercial manifestation of the Wyss platform.
• Manifold Bio: Wyss spinout commercializing multiplexed protein binding and barcoding platform for protein therapeutic discovery. Raised $40M Series A; direct peer demonstrating the institute's protein-engineering capabilities and AI-augmented discovery thesis.
• Dyno Therapeutics: Wyss spinout commercializing AI-powered AAV capsid engineering for gene therapy delivery. Direct peer within the Wyss spinout portfolio and comparable AI-meets-biotech model; provides additional validation of the Wyss translation engine.
• CN Bio: Commercial competitor offering organ-on-chip and microphysiological systems for drug development. Closely comparable to Emulate in product category (Organ Chips) and target customer (top biopharma), providing a direct head-to-head benchmark.
• Broad Institute of MIT and Harvard: Cambridge-based biomedical and genomic research institute co-affiliated with Harvard and MIT. Closely comparable academic translational research engine; Wyss collaborated with Broad on ML-driven antibiotic discovery for drug-resistant gonorrhea.
• Mimetas: Dutch organ-on-chip company providing microfluidic 3D tissue models for drug discovery. Comparable to Wyss/Emulate on Organ Chip product category and pharma/biotech customer base, with strong presence in European pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/wyssinstitute
• YouTubevimeo.com/wyssinstitute
• Facebookfacebook.com/wyssinstitute
• LinkedInlinkedin.com/company/wyssinstitute
• Instagraminstagram.com/wyssinstitute

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries7 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wyss Institute